

MAY 16 2005

K 030900 1/2



Asclepion Laser Technologies GmbH • Göschwitzer Str. 51-52 • D-07745 Jena

### 510(k) SUMMARY

#### ASCLEPION LASER TECHNOLOGIES GmbH MeDioStar XT Laser System

This 510(k) summary of safety and effectiveness for the Asclepion Laser Technologies GmbH MeDioStar XT Laser System is submitted in accordance with the requirements of 21 CFR 907.92 and follows Office of Device Evaluation Guidance concerning the organization and content of a 510(k) summary.

Applicant: ASCLEPION LASER TECHNOLOGIES GmbH  
Goeschwitzer Str. 51-52  
07745 Jena, Germany

Contact Person: Mr Reinhard Thieme  
Quality Assurance and  
International Regulatory Affairs

Phone: +49 3641 220 211  
Fax: +49 3641 220 322  
e-mail: reinhard.thieme@asclepion.com

Preparation Date: March 23, 2005

Device Name: MeDioStar XT Laser System

Common Name: MeDioStar XT

Classification Name: Instrument, surgical, powered, laser  
79-GEX  
21 CFR 878.481

Equivalent Device: MeDioStar H Laser System  
(with and without skin cooling system)

Device Description: MeDioStar XT Laser System is a pulsed diode laser with a wavelength of 808µm. It consists a laser enclosure and optic delivery system (fiber bundle and handpiece).

000087

K 650 960 2/2

Intended Use:	The MeDioStar XT Laser System is intended to remove unwanted body hair and vascular lesions.
Comparison to:	The MeDioStar XT Laser System is substantially equivalent to the MeDioStar H Laser System (with and without skin cooling), with the same principles of operation, the same wavelength and essentially the same power range as the predicate device for the same indications for uses.
Nonclinical Performance Data:	None
Clinical Performance Data:	None
Conclusion:	The MeDioStar XT Laser System is another safe and effective device for the removal of unwanted body hair and the treatment of vascular lesions.
Additional Information:	None



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 16 2005

Mr. Reinhard Thieme  
Quality Assurance and International Regulatory Affairs  
Asclepion Laser Technologies GmbH  
Goeschwitzerstrasse 51-52  
Jena, Germany 07745

Re: K050900

Trade/Device Name: MeDioStar XT Laser System

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology

Regulatory Class: II

Product Code: GEX

Dated: April 26, 2005

Received: April 28, 2005

Dear Mr. Thieme:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Reinhard Thieme

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115 . Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Miriam C. Provost, Ph.D.  
Acting Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K050960

Device Name: MeDioStar XT Laser System

Indications for Use:

The MeDioStar XT Laser System is intended to remove unwanted body hair and vascular lesions.

Prescription Use X AND/OR Over-The-Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



Division Director (D)  
Division of General, Restorative  
and Technological Devices

1

K050960

000090